Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment - fda.gov

Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment  fda.gov

London patient remains HIV-free after 2.5 years off treatment - Aidsmap

London patient remains HIV-free after 2.5 years off treatment  Aidsmap

A Hidden Defense Inside Llamas Could Be The Secret to Fighting HIV - ScienceAlert

A Hidden Defense Inside Llamas Could Be The Secret to Fighting HIV  ScienceAlert

Test and treat studies show high rates of HIV diagnosis, viral suppression - Aidsmap

Test and treat studies show high rates of HIV diagnosis, viral suppression  Aidsmap

After viral rebound, dolutegravir-based treatment more likely to suppress HIV - Aidsmap

After viral rebound, dolutegravir-based treatment more likely to suppress HIV  Aidsmap

Some children who start antiretrovirals very early may control HIV after stopping treatment - Aid...

Some children who start antiretrovirals very early may control HIV after stopping treatment  Aidsmap

Therapeutic vaccine shows potential for HIV control off treatment in early study - Aidsmap

Therapeutic vaccine shows potential for HIV control off treatment in early study  Aidsmap

Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two year...

Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two years later  Aidsmap

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatme...

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatment  Aidsmap

Lung function declines faster in people living with HIV - Aidsmap

Lung function declines faster in people living with HIV  Aidsmap

One person remains undetectable without HIV drugs almost four years after using an antibody-based...

One person remains undetectable without HIV drugs almost four years after using an antibody-based therapy  Aidsmap

New cases of multi-drug resistant HIV becoming rarer in Europe - Aidsmap

New cases of multi-drug resistant HIV becoming rarer in Europe  Aidsmap

Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta - Aidsmap

Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta  Aidsmap

Have HIV-associated neurological disorders declined in people with HIV due to recent antiretrovir...

Have HIV-associated neurological disorders declined in people with HIV due to recent antiretrovirals?  Aidsmap

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it - Aidsmap

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it  Aidsmap

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds...

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds  Aidsmap

Long-acting injectable treatment maintains viral suppression - Aidsmap

Long-acting injectable treatment maintains viral suppression  Aidsmap

German man remains free of HIV nearly 10 years after stem cell transplant - Aidsmap

German man remains free of HIV nearly 10 years after stem cell transplant  Aidsmap

The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance be...

The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?  Aidsmap

Experts shed light on coronavirus response and its implications for people with HIV - Aidsmap

Experts shed light on coronavirus response and its implications for people with HIV  Aidsmap

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing ...

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy  Aidsmap

Biktarvy combination pill may be most effective option for people with HIV and hepatitis B - Aidsmap

Biktarvy combination pill may be most effective option for people with HIV and hepatitis B  Aidsmap

Reappearance of HIV in "Mississippi Baby" poses questions for early treatment - Aidsmap

Reappearance of HIV in "Mississippi Baby" poses questions for early treatment  Aidsmap

Fostemsavir salvage therapy continues to look good at 96 weeks - Aidsmap

Fostemsavir salvage therapy continues to look good at 96 weeks  Aidsmap

Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for ...

Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for cause  Aidsmap

People with HIV express high satisfaction with monthly injectable regimen - Aidsmap

People with HIV express high satisfaction with monthly injectable regimen  Aidsmap

African studies show that lowering viral load in the community reduces HIV incidence, but is not ...

African studies show that lowering viral load in the community reduces HIV incidence, but is not enough to eliminate HIV  Aidsmap

The amber light: the World Health Organization’s position when an HIV viral load is “suppressed b...

The amber light: the World Health Organization’s position when an HIV viral load is “suppressed but not undetectable”  Aidsmap

HIV incidence fell by three-quarters in Australian gay men, with strong association with treatmen...

HIV incidence fell by three-quarters in Australian gay men, with strong association with treatment as prevention  Aidsmap

Broadly neutralising antibodies may be partners for long-acting antiretrovirals - Aidsmap

Broadly neutralising antibodies may be partners for long-acting antiretrovirals  Aidsmap

Woman with HIV with low CD4 count remained positive on SARS-CoV-2 tests for over 5 months - Aidsmap

Woman with HIV with low CD4 count remained positive on SARS-CoV-2 tests for over 5 months  Aidsmap

Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up - Aidsmap

Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up  Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care - Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care  Aidsmap

Opportunistic infections remain common in people taking HIV treatment in Latin America - Aidsmap

Opportunistic infections remain common in people taking HIV treatment in Latin America  Aidsmap

Poor adherence associated with disruptive life events in young people living with HIV - Aidsmap

Poor adherence associated with disruptive life events in young people living with HIV  Aidsmap

Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe - Aidsmap

Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe  Aidsmap

Diagnosis and treatment for high blood pressure need to be funded as part of HIV treatment progra...

Diagnosis and treatment for high blood pressure need to be funded as part of HIV treatment programmes  Aidsmap

Who is at risk of injectable treatment failure? - Aidsmap

Who is at risk of injectable treatment failure?  Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over - Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over  Aidsmap

Options for two-drug simplification expand - Aidsmap

Options for two-drug simplification expand  Aidsmap

Fact check: List of US patents is not evidence that viruses are manmade - Reuters

Fact check: List of US patents is not evidence that viruses are manmade  Reuters

Viral suppression in Uganda improved by more viral load tests, done faster - Aidsmap

Viral suppression in Uganda improved by more viral load tests, done faster  Aidsmap

Antiviral Drugs Market Size, Share, Growth, Forecast, 2032 - Fortune Business Insights

Antiviral Drugs Market Size, Share, Growth, Forecast, 2032  Fortune Business Insights